Loading...
Market
Will Recursion Pharmaceuticals' stock price increase by at least 20% by December 31, 2024, following the merger announcement?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from financial platforms such as Yahoo Finance, Bloomberg, or Reuters
Story
Recursion and Exscientia to Merge in $688 Million All-Stock Deal
Aug 8, 2024, 12:02 PM
Recursion Pharmaceuticals and Exscientia have entered a definitive agreement to merge, creating a global leader in technology-enabled drug discovery. The merger, valued at $688 million, is an all-stock deal that will combine Recursion's high throughput target biology and supercomputing capabilities with Exscientia's generative AI drug design and chemistry automation. The collaboration is expected to enhance the companies' end-to-end capabilities in the biotech sector, marking a significant milestone in the use of AI in drug development.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $10 • 25%
$10 to $15 • 25%
$15 to $20 • 25%
Above $20 • 25%
Yes • 50%
No • 50%
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Yes • 50%
No • 50%
